JP5377173B2 - 生物学的製剤 - Google Patents
生物学的製剤 Download PDFInfo
- Publication number
- JP5377173B2 JP5377173B2 JP2009205660A JP2009205660A JP5377173B2 JP 5377173 B2 JP5377173 B2 JP 5377173B2 JP 2009205660 A JP2009205660 A JP 2009205660A JP 2009205660 A JP2009205660 A JP 2009205660A JP 5377173 B2 JP5377173 B2 JP 5377173B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibody molecule
- cdr
- dna
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
CD22はほとんどのB細胞白血病とリンパ腫[NHL、急性リンパ性白血病(B−ALL)、慢性リンパ性白血病(B−CLL)、および特に急性非リンパ性白血病(ANLL)を含む]で発現される。
本発明の第1と第2の態様の抗体分子は、好ましくはそれぞれ相補的軽鎖または相補的重鎖を有する。
実施例1:候補抗体の生成
以下の選択基準を利用して、CD22に対する抗体の一団をハイブリドーマから選択した:ダウディ(Daudi)細胞への結合、ダウディ細胞でのインターナリゼーション、末梢血単核細胞(PBMC)への結合、PBMCでのインターナリゼーション、親和性(10-9Mを超える)、マウスγ1および産生速度。5/44を好ましい抗体として選択した。
5/44ハイブリドーマ細胞の調製およびそこからのRNA調製
5/44抗CD22モノクローナル抗体を用いる染色の出現率と分布を調べるために免疫組織化学試験に着手した。腫瘍のB細胞領域を確認するために、試験には対照の抗CD20および抗CD79a抗体を含めた。
・ 4個 B−CLL/小リンパ球性リンパ腫(低/A)
・ 3個 リンパ形質細胞様/免疫細胞腫(低/A)
・ 1個 外套細胞(中/F)
・ 14個 濾胞性リンパ腫(低〜中/D)
・ 13個 びまん性大細胞型リンパ腫(中〜高/G、H)
・ 6個 分類不能(K)
・ 2個 T細胞リンパ腫
5/44重鎖と軽鎖の可変ドメインをコードするcDNA配列は、逆転写酵素を用いて全RNA中に存在するmRNAの1本鎖cDNAコピーを生成させることにより合成した。次にこれを、ポリメラーゼ連鎖反応(Polymerase Chain Reaction)(PCR)による特異的なオリゴヌクレオチドプライマーを用いてマウスV領域配列の増幅のための鋳型として使用した。
cDNAは、以下の試薬:50mMトリス−HCl(pH8.3)、75mM KCl、10mMジチオスレイトール、3mM MgCl2、0.5mMの各デオキシリボヌクレオシド三リン酸、20単位のRNAsin、75ngランダムヘキサヌクレオチドプライマー、2μgの5/44RNAおよび200単位のマウスモロニー白血病ウイルス逆転写酵素を含む20μlの反応容量中で合成した。42℃で60分間インキュベート後、95℃で5分間加熱して、反応を停止させた。
cDNAのアリコートを、重鎖と軽鎖に特異的なプライマーの組合せを用いるPCRにかけた。シグナルペプチドの保存配列とアニーリングするために設計された変性したプライマープールを前進プライマーとして使用した。これらの配列は全て、順に、5’末端から7ヌクレオチドで開始する制限部位(VLSFuI;VHHindIII)、生じたmRNAの最適な翻訳を可能にする配列:GCCGCCACC(配列番号50)、開始コドン、および既知のマウス抗体のリーダーペプチド配列に基づく20〜30ヌクレオチドを含む(カバト(Kabat)ら、「免疫学的関心のあるタンパク質の配列(Sequences of Proteins of Immunological Interest)」、第5版、1991年、米国保健社会福祉省(U.S. Department of Health and Human Services)、公衆衛生局(Public Health Service)、国立衛生研究所(National Institutes of Health))。
次にマウスV領域配列を、発現ベクターpMRR10.1およびpMRR14中にクローン化した(図7)。これらは、ヒトカッパ軽鎖とヒトガンマ−4重鎖の定常領域をコードするDNAを含む、それぞれ軽鎖と重鎖の発現用のベクターである。VL領域は、SfuIとBsiWI制限部位を用いて、配列決定ベクターからの制限消化と連結により、発現ベクター中にサブクローン化して、プラスミドpMRR10(544cL)を作成した。重鎖DNAは、5’プライマーを用いてPCRにより増幅することによりシグナルペプチドを導入したが、これは、異なる社内のハイブリドーマ(162と呼ばれる)からのマウス重鎖抗体リーダーを使用したクローニング方策では得られなかったためである。5’プライマーは、以下の配列を有する:
可能なN結合グリコシル化部位配列は、アミノ酸配列N−Y−Tを有するCDR−H2に観察された(図3)。5/44およびその断片(Fabを含む)のゲルの、SDS−PAGE、ウェスタンブロッティングおよび炭水化物染色は、この部位が実際にグリコシル化されていることを示している(図示せず)。さらにリジン残基は、CDR−H2内の露出位置に観察されたが、これは、抗体が結合体形成しうる物質との結合体形成のための追加の部位を提供することにより、抗体の結合親和性を低下させる潜在力を有する。
キメラ遺伝子の活性は、CHO細胞への一過性トランスフェクションにより評価した。
グリコシル化部位または反応性リジンを除去したキメラ5/44またはその変種の親和性は、CD22−mFc構築体への結合についてBIA法を用いて調査した。結果を図8に示す。全ての結合測定は、BIAコア(BIAcore)(登録商標)2000機器(ファルマシア・バイオセンサー(Pharmacia Biosensor AB)、ウプサラ、スウェーデン)で実施した。このアッセイは、固定化抗マウスFcを介したCD22mFcの捕捉により実施した。抗体は可溶性相に入れた。試料、標準物質、および対照(50ul)を固定化抗マウスFcに注入し、続いて可溶性相の抗体を加えた。各サイクル後に、表面を50ulの40mM HClで30ul/分で再生した。反応速度分析は、BIA評価3.1ソフトウェア(ファルマシア(Pharmacia))を用いて実施した。
5/44抗体の重鎖と軽鎖の可変領域の遺伝子の分子クローニング、およびキメラ(マウス/ヒト)5/44抗体を産生するためのその使用を上記した。マウス5/44のVLおよびVHドメインのヌクレオチドおよびアミノ酸配列は、それぞれ図2と3に示される(配列番号7と8)。この実施例は、アデア(Adair)ら(WO91/09967)の方法による、ヒトにおける潜在的な免疫原性を低下させるためのヒトフレームワークへの5/44抗体のCDR移植を説明する。
ヒトサブグループIカッパ軽鎖V領域からのコンセンサス配列とのタンパク質配列の整列は、64%の配列同一性を示した。その結果、CDR移植軽鎖を作成するために選択したアクセプターフレームワーク領域は、ヒトVKサブグループI生殖細胞系O12、DPK9配列のものに対応した。フレームワーク4のアクセプター配列は、ヒトJ領域生殖細胞系配列JK1から誘導した。
5/44重鎖のCDR移植は、軽鎖に関して記述されたものと同じ方策を用いて行った。5/44重鎖のVドメインは、サブグループIに属するヒト重鎖と相同である(70%の配列同一性)ことが見い出されたため、ヒトサブグループI生殖細胞系フレームワークVH1−3、DP7の配列をアクセプターフレームワークとして使用した。フレームワーク4アクセプター配列は、ヒトJ領域生殖細胞系配列JH4から誘導した。
遺伝子は、移植配列gH1とgL1をコードするように設計し、一連の重複オリゴヌクレオチドを設計し構築した(図9)。PCR組立法を利用することにより、CDR移植V領域遺伝子を作成した。10mMトリス−HCl(pH8.3)、1.5mM MgCl2、50mM KCl、0.001%ゼラチン、0.25mM各デオキシリボヌクレオシド三リン酸、1pmol各「内部」プライマー(T1、T2、T3、B1、B2、B3)、10pmol各「外部」プライマー(F1、R1)、および1単位のTaqポリメラーゼ(アンプリTaq(AmpliTaq)、アプライド・バイオシステムズ(Applied BioSystems)、カタログ番号N808−0171)を含む、100ulの反応容量を設定した。PCRサイクルパラメータは、94℃で1分、55℃で1分、72℃で1分を30サイクルであった。次に反応産物を1.5%アガロースゲルに流して、切り出し、キアゲン(QIAGEN)スピンカラム(QIAクイック(QIAquick)ゲル抽出キット、カタログ番号28706)を用いて回収した。DNAを30μlの容量で溶出した。次にgH1とgL1 DNAのアリコート(1μl)を、インビトロジェン(InVitrogen)TOPO TAクローニングベクターpCR2.1 TOPO(カタログ番号K4500−01)中に製造業者の説明書によってクローン化した。この非発現ベクターは、多数のクローンの配列決定を促進するためのクローニング中間体の役目を果たした。ベクター特異的プライマーを用いるDNA配列決定を使用することにより、gH1とgL1を含む誤りのないクローンを同定して、プラスミドpCR2.1(544gH1)とpCR2.1(544gL1)を作成した(図10)。
移植変種をコードするベクターを、元々のキメラ抗体鎖と一緒に種々の組合せでCHO細胞中に同時トランスフェクトした。結合活性は、元々のマウス5/44抗体の結合をラモス(Ramos)細胞(ATCCから入手;表面CD22を発現するバーキット(Burkitt's)リンパ腫リンパ芽球ヒト細胞株)への結合に関して競合させて、競合アッセイで比較した。このアッセイは、移植片をその細胞表面CD22に結合する能力において比較するための最良の方法と考えられた。結果を図8に示す。明らかなように、移植片のいずれの間にもほとんど差がなく、全てがマウスの親に対する競合でキメラより有効に奏効する。CDR−H3(gH5とgH7)の末端に3個の追加のヒト残基を導入しても、結合に影響はないようである。
Claims (18)
- 配列番号28に示される配列における21位〜239位の残基を含む軽鎖と、配列番号30に示される配列における20位〜467位の残基を含む重鎖とを含む、ヒトCD22に対する特異性を有する抗体分子。
- 配列番号28に示される配列における21位〜239位の残基を含む軽鎖と、配列番号30に示される配列における20位〜467位の残基を含む重鎖とからなる、請求項1に記載の抗体分子。
- 請求項1又は2の抗体分子の重鎖および/または軽鎖をコードするDNA
。 - 請求項3のDNAを含むクローニングベクターまたは発現ベクター。
- 請求項4のクローニングベクターまたは発現ベクターを含む宿主細胞。
- 治療で使用される、請求項1又は2の抗体分子。
- 悪性リンパ腫を治療するのに使用される、請求項1又は2の抗体分子。
- 悪性リンパ腫は非ホジキンリンパ腫である、請求項7の抗体分子。
- 治療で使用される、請求項3のDNA。
- 悪性リンパ腫を治療するのに使用される、請求項3のDNA。
- 悪性リンパ腫は非ホジキンリンパ腫である、請求項10のDNA。
- CD22を発現する細胞により仲介される病態の治療のための、ヒトCD22に対する
特異性を有する請求項1又は2の抗体分子、または請求項3のDNAを含む医薬組成物。 - 病態が悪性リンパ腫である、請求項12の医薬組成物。
- 病態が非ホジキンリンパ腫である、請求項13の医薬組成物。
- 請求項1又は2のいずれか1項の抗体分子または請求項3のDNAを含む診断用組成物
。 - 薬剤学的に許容される賦形剤、希釈剤または担体を含む、請求項12〜14のいずれかに記載の医薬組成物。
- 抗T細胞、抗IFNγ、または抗LPS抗体、またはキサンチンのような非抗体成分を
さらに含む、請求項12〜14のいずれかに記載の医薬組成物。 - 請求項1又は2の抗体分子の製造方法であって、該抗体分子をコードする
DNAからのタンパク質の発現に適した条件下で請求項5の宿主細胞を培養し、該抗体
分子を単離することを特徴とする、上記方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0210121.0 | 2002-05-02 | ||
GBGB0210121.0A GB0210121D0 (en) | 2002-05-02 | 2002-05-02 | Biological products |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004501459A Division JP4486494B2 (ja) | 2002-05-02 | 2003-05-02 | 生物学的製剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013140245A Division JP5920934B2 (ja) | 2002-05-02 | 2013-07-04 | 生物学的製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010022372A JP2010022372A (ja) | 2010-02-04 |
JP2010022372A5 JP2010022372A5 (ja) | 2010-04-22 |
JP5377173B2 true JP5377173B2 (ja) | 2013-12-25 |
Family
ID=9935990
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004501459A Expired - Lifetime JP4486494B2 (ja) | 2002-05-02 | 2003-05-02 | 生物学的製剤 |
JP2009205660A Expired - Lifetime JP5377173B2 (ja) | 2002-05-02 | 2009-09-07 | 生物学的製剤 |
JP2013140245A Expired - Lifetime JP5920934B2 (ja) | 2002-05-02 | 2013-07-04 | 生物学的製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004501459A Expired - Lifetime JP4486494B2 (ja) | 2002-05-02 | 2003-05-02 | 生物学的製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013140245A Expired - Lifetime JP5920934B2 (ja) | 2002-05-02 | 2013-07-04 | 生物学的製剤 |
Country Status (35)
Country | Link |
---|---|
US (8) | US7355011B2 (ja) |
EP (1) | EP1504035B9 (ja) |
JP (3) | JP4486494B2 (ja) |
KR (3) | KR101238970B1 (ja) |
CN (3) | CN103172742B (ja) |
AT (1) | ATE462729T3 (ja) |
AU (1) | AU2003223007C1 (ja) |
BE (1) | BE2017C068I2 (ja) |
CA (1) | CA2484420C (ja) |
CO (1) | CO5631451A2 (ja) |
CY (3) | CY1110134T1 (ja) |
DE (1) | DE60331910D1 (ja) |
DK (1) | DK1504035T6 (ja) |
EC (1) | ECSP045470A (ja) |
ES (1) | ES2341708T7 (ja) |
FR (1) | FR17C1062I2 (ja) |
GB (1) | GB0210121D0 (ja) |
HK (2) | HK1071762A1 (ja) |
HU (2) | HUS1700055I1 (ja) |
IL (1) | IL164923A (ja) |
LT (2) | LTC1504035I2 (ja) |
LU (2) | LUC00058I2 (ja) |
MX (1) | MXPA04010787A (ja) |
NL (1) | NL300920I2 (ja) |
NO (1) | NO336201B1 (ja) |
NZ (1) | NZ536757A (ja) |
PL (1) | PL218433B1 (ja) |
PT (1) | PT1504035E (ja) |
RU (1) | RU2342401C2 (ja) |
SG (1) | SG161744A1 (ja) |
SI (1) | SI1504035T1 (ja) |
TW (1) | TWI324161B (ja) |
UA (1) | UA92580C2 (ja) |
WO (1) | WO2003093320A2 (ja) |
ZA (1) | ZA200408851B (ja) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1448584B1 (en) | 2001-09-26 | 2010-05-19 | The Government of the United States of America as represented by The Secretary of Health and Human Services | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
CA2476776A1 (en) | 2002-02-21 | 2003-09-04 | Duke University | Reagents and treatment methods for autoimmune diseases |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
PL224001B1 (pl) | 2002-05-02 | 2016-11-30 | Wyeth Corp | Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
AR052774A1 (es) * | 2004-10-08 | 2007-04-04 | Wyeth Corp | Inmunoterapia para trastornos autoinmunes |
EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
EP2639242A3 (en) * | 2006-03-06 | 2013-10-16 | MedImmune, Inc. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
CA2652945C (en) * | 2006-05-30 | 2015-06-02 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
CN101626782B (zh) | 2006-12-01 | 2013-03-27 | 梅达雷克斯公司 | 结合cd22的人抗体及其用途 |
US8591889B2 (en) | 2008-04-04 | 2013-11-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies specific for CD22 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
MX353186B (es) | 2009-09-03 | 2018-01-05 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
JP6162606B2 (ja) | 2011-01-14 | 2017-07-12 | レッドウッド バイオサイエンス, インコーポレイテッド | アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 |
EP2680884B1 (en) | 2011-02-28 | 2018-01-17 | F. Hoffmann-La Roche AG | Biological markers and methods for predicting response to b-cell antagonists |
JP2015516984A (ja) * | 2012-04-26 | 2015-06-18 | バイオアトラ、エルエルシー | 抗cd22抗体 |
WO2014008404A1 (en) | 2012-07-03 | 2014-01-09 | Washington University | Antibodies to tau |
CN104582717B (zh) | 2012-07-19 | 2018-03-13 | 雷德伍德生物科技股份有限公司 | 对cd22有特异性的抗体及其使用方法 |
RU2658485C2 (ru) * | 2012-10-24 | 2018-06-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы м971 |
CN103214578B (zh) * | 2013-05-10 | 2014-05-28 | 北京东方百泰生物科技有限公司 | 一种新型的人源化抗cd22抗体 |
TW201605480A (zh) | 2013-11-04 | 2016-02-16 | 輝瑞大藥廠 | 抗efna4抗體-藥物結合物 |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
KR20170134642A (ko) * | 2015-04-08 | 2017-12-06 | 노파르티스 아게 | Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법 |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール.ピー.シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
GB201610512D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
US20180110856A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical Formulations and Methods of Making the Same |
MX2020010227A (es) | 2018-03-30 | 2021-02-17 | Eureka Therapeutics Inc | Construcciones dirigidas a cd22 y usos de las mismas. |
JP2023521635A (ja) * | 2020-04-02 | 2023-05-25 | ナンチン イアソ バイオセラピューティクス カンパニー,リミティド | 全ヒト化抗ヒトcd22のキメラ抗原受容体及びその応用 |
CN114106177B (zh) * | 2020-08-27 | 2024-04-09 | 深圳市菲鹏生物治疗股份有限公司 | Cd22抗体及其应用 |
WO2022262783A1 (zh) * | 2021-06-16 | 2022-12-22 | 西安宇繁生物科技有限责任公司 | 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用 |
AU2022333837A1 (en) * | 2021-08-27 | 2024-03-14 | Peptron, Inc. | Novel anti-muc1 antibody and use thereof |
US20240166705A1 (en) | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957362A (en) * | 1972-10-02 | 1976-05-18 | Corneal Sciences, Inc. | Hydrogels and articles made therefrom |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5134075A (en) * | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ES2264239T3 (es) * | 1990-06-27 | 2006-12-16 | Princeton University | Complejo de proteinas p53/p90'. |
HU219537B (hu) * | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5714340A (en) * | 1992-12-22 | 1998-02-03 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassay elements having a receptor zone |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
DK1759709T3 (da) | 1994-01-25 | 2013-06-10 | Elan Pharm Inc | Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4 |
ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
AU3272695A (en) * | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US20020141990A1 (en) * | 1996-11-01 | 2002-10-03 | Smithkline Beecham Corporation | Anti-RSV human monoclonal antibodies |
EP0977590A4 (en) * | 1996-11-01 | 2001-03-14 | Smithkline Beecham Corp | HUMAN MONOCLONAL ANTIBODIES |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
AU740904B2 (en) * | 1997-03-20 | 2001-11-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
ES2190087T3 (es) | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
AT408613B (de) * | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
KR100345463B1 (ko) * | 1998-11-19 | 2003-01-08 | 주)녹십자 | B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법 |
EP1194167B1 (en) * | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
DK1232392T3 (da) * | 1999-10-12 | 2003-07-28 | Connex Ges Zur Optimierung Von | Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring |
WO2002004021A1 (en) * | 2000-07-12 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
CN1205479C (zh) * | 2000-10-31 | 2005-06-08 | 杨梦甦 | 免疫学诊断蛋白芯片制备方法 |
PL224001B1 (pl) | 2002-05-02 | 2016-11-30 | Wyeth Corp | Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
US8389688B2 (en) * | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
-
2002
- 2002-05-02 GB GBGB0210121.0A patent/GB0210121D0/en not_active Ceased
-
2003
- 2003-05-02 EP EP03718974.3A patent/EP1504035B9/en not_active Expired - Lifetime
- 2003-05-02 US US10/428,408 patent/US7355011B2/en active Active
- 2003-05-02 KR KR1020107027192A patent/KR101238970B1/ko active IP Right Grant
- 2003-05-02 UA UA20041209866A patent/UA92580C2/ru unknown
- 2003-05-02 MX MXPA04010787A patent/MXPA04010787A/es active IP Right Grant
- 2003-05-02 AT AT03718974T patent/ATE462729T3/de unknown
- 2003-05-02 ES ES03718974.3T patent/ES2341708T7/es active Active
- 2003-05-02 CN CN201310021287.1A patent/CN103172742B/zh not_active Expired - Lifetime
- 2003-05-02 CN CN2007100852904A patent/CN101134779B/zh not_active Expired - Lifetime
- 2003-05-02 AU AU2003223007A patent/AU2003223007C1/en active Active
- 2003-05-02 TW TW092112182A patent/TWI324161B/zh not_active IP Right Cessation
- 2003-05-02 RU RU2004135103/13A patent/RU2342401C2/ru active
- 2003-05-02 CN CNB038150433A patent/CN100384878C/zh not_active Expired - Lifetime
- 2003-05-02 PL PL373277A patent/PL218433B1/pl unknown
- 2003-05-02 SI SI200331804T patent/SI1504035T1/sl unknown
- 2003-05-02 DE DE60331910T patent/DE60331910D1/de not_active Expired - Lifetime
- 2003-05-02 PT PT03718974T patent/PT1504035E/pt unknown
- 2003-05-02 DK DK03718974.3T patent/DK1504035T6/en active
- 2003-05-02 KR KR1020047017615A patent/KR101156796B1/ko active IP Right Grant
- 2003-05-02 SG SG200608406-5A patent/SG161744A1/en unknown
- 2003-05-02 WO PCT/GB2003/001934 patent/WO2003093320A2/en active Application Filing
- 2003-05-02 CA CA2484420A patent/CA2484420C/en not_active Expired - Lifetime
- 2003-05-02 JP JP2004501459A patent/JP4486494B2/ja not_active Expired - Lifetime
- 2003-05-02 KR KR1020127025129A patent/KR101386376B1/ko active IP Right Grant
- 2003-05-02 NZ NZ536757A patent/NZ536757A/en not_active IP Right Cessation
-
2004
- 2004-10-28 IL IL164923A patent/IL164923A/en active IP Right Grant
- 2004-11-02 ZA ZA2004/08851A patent/ZA200408851B/en unknown
- 2004-11-02 NO NO20044742A patent/NO336201B1/no not_active IP Right Cessation
- 2004-11-30 CO CO04120665A patent/CO5631451A2/es active IP Right Grant
- 2004-12-02 EC EC2004005470A patent/ECSP045470A/es unknown
-
2005
- 2005-05-27 HK HK05104462.6A patent/HK1071762A1/xx not_active IP Right Cessation
-
2006
- 2006-09-11 US US11/519,585 patent/US20070059307A1/en not_active Abandoned
-
2008
- 2008-09-23 US US12/235,724 patent/US7919606B2/en not_active Expired - Lifetime
-
2009
- 2009-09-07 JP JP2009205660A patent/JP5377173B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-03 CY CY20101100492T patent/CY1110134T1/el unknown
-
2011
- 2011-03-16 US US13/049,087 patent/US8895714B2/en active Active
-
2012
- 2012-07-13 US US13/548,542 patent/US20120302739A1/en not_active Abandoned
-
2013
- 2013-07-04 JP JP2013140245A patent/JP5920934B2/ja not_active Expired - Lifetime
- 2013-12-12 HK HK13113804.4A patent/HK1186479A1/zh not_active IP Right Cessation
-
2016
- 2016-03-14 US US15/069,078 patent/US20160326247A1/en not_active Abandoned
-
2017
- 2017-01-27 US US15/417,973 patent/US20170145114A1/en not_active Abandoned
- 2017-12-20 CY CY2017046C patent/CY2017046I2/el unknown
- 2017-12-21 CY CY2017045C patent/CY2017045I2/el unknown
- 2017-12-21 BE BE2017C068C patent/BE2017C068I2/nl unknown
- 2017-12-21 NL NL300920C patent/NL300920I2/nl unknown
- 2017-12-21 LT LTPA2017044C patent/LTC1504035I2/lt unknown
- 2017-12-21 LT LTPA2017043C patent/LTPA2017043I1/lt unknown
- 2017-12-21 FR FR17C1062C patent/FR17C1062I2/fr active Active
- 2017-12-21 LU LU00058C patent/LUC00058I2/en unknown
- 2017-12-21 LU LU00057C patent/LUC00057I2/en unknown
- 2017-12-22 HU HUS1700055C patent/HUS1700055I1/hu unknown
- 2017-12-22 HU HUS1700056C patent/HUS1700056I1/hu unknown
-
2021
- 2021-01-19 US US17/151,911 patent/US20210371547A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210371547A1 (en) | Biological products | |
JP6133340B2 (ja) | Cd37結合分子及びそのイムノコンジュゲート | |
BRPI0309730B1 (pt) | Molécula de anticorpo possuindo especificidade para cd22 humana, sequência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120413 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120712 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120718 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120810 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120815 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120913 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130212 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130704 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130806 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130830 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130924 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5377173 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |